Investigational drugs for the treatment of Zika virus infection: a preclinical and clinical update.
Yingshan HanThibault MespledePublished in: Expert opinion on investigational drugs (2018)
So far, 20 compounds have been tested in vivo and three in the clinical trials; progressing these compounds to the clinic is a challenge. Novel ZIKV inhibitors that target virus or host factors are urgently needed. Knowledge-driven drug repurposing, structure-based discovery, RNA interference, long noncoding RNAs, miRNAs, and peptide inhibitors may pave the way for the discovery of such novel agents.